NVO
NOVO NORDISK A SPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jul 21 to Jul 31 4 court rulings: NOVO NORDISK INC. et al v. APOTEX INC.; Griffin Health Services Corporation et al v. Novo Nordisk… and 2 more
- Aug 26 ▲ C. Franklin bought $1,001 - $15,000, last disclosed Sep 18
- Sep 3 to Sep 8 2 court rulings: Novo Nordisk A/S et al v. Mochi Health Corp. et al; Novo Nordisk A/S et al v. Aios Inc. et al
- Sep 8 Trial readout: Results Pending: Oral semaglutide (Phase 3), Completed 71d…
- Sep 10 Trial readout: Results Pending: CagriSema (Cagrilintide B and Semaglutide…
- Sep 11 ▼ Morgan Stanley downgrades
- Sep 17 ▲ Novo Nordisk announced that the EMA's CHMP has adopted a positive op…
- Sep 23 Novo Nordisk A/S et al v. Aios Inc. et al
- Sep 30 ▲ 4 funds open new positions (13F)
- Oct 26 NOVO NORDISK INC. v. ELI LILLY AND COMPANY et al
- Nov 4 ▲ Novo Nordisk reported Q3 2026 adjusted operating profit up 27% at CE…
- Nov 13 to Nov 13 2 court rulings: Novo Nordisk A/S et al v. Mochi Health Corp. et al; Novo Nordisk A/S et al v. MD Exam LLC
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q3 2026: 48 added (4 new), 34 trimmed or exited. Largest new: Imc-Chicago $16.6M, Fiera Capital $14.8M.
- AnalystsMIXED
10 of 36 rate it Buy or better.
- Short sellersSTEADY
Short interest +2.3% to 38.29M shares. 4.0 days to cover, ≈0.9% of shares.
- TrendUPTREND
4% above its 50-day average.
- SocialQUIET
Crowd 55° (neutral) this week from 6 mentions: 1 bullish, 0 bearish. No setup is alerting.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | $648.0M |
| RENAISSANCE TECHNOLOGIES LLC | ADD | $177.3M |
| BARCLAYS PLC | ADD | $130.0M |
| NATIXIS | DOUBLED | $90.7M |
| MARSHALL WACE, LLP | ADD | $82.0M |
| AMERICAN CENTURY COMPANIES INC | ADD | $69.6M |
| VAN ECK ASSOCIATES CORP | ADD | $57.8M |
| WCM INVESTMENT MANAGEMENT, LLC | ADD | $56.9M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
36 analysts| Date | Firm | Rating |
|---|---|---|
| Oct 12, 2026 | BMO Capital MAINTAIN | Market Perform |
| Sep 11, 2026 | Morgan Stanley DOWNGRADE | Underweight |
Washington
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
43 filings · 4 bullish · 3 bearish · 1 mixed · 35 neutral- NEUTRAL 6-KNov 16, 2026
Novo Nordisk filed a routine 6-K updating its ongoing share repurchase program. Since the prior weekly update, the company repurchased 1.13 million B shares for approximately DKK 310 million, bringing the total under the program to 28.975 million shares for DKK 8.32 billion.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL COURT-RULINGNov 13, 2026
A federal magistrate judge recommended granting summary judgment on liability to Novo Nordisk…
The liability ruling is a positive step for Novo Nordisk in protecting its GLP-1 franchise from compounded semaglutide sellers, but the financial impact depends on the remedies phase. Monitor for…
- NEUTRAL COURT-RULINGNov 13, 2026
The court entered a stipulated protective order in Novo Nordisk's patent litigation against Mochi…
Monitor the case for substantive rulings on patent validity and infringement, which could affect Novo Nordisk's market exclusivity for semaglutide products. The protective order is routine and has…
- NEUTRAL 6-KNov 9, 2026
Novo Nordisk filed a routine 6-K updating its ongoing share repurchase program, reporting the…
This is a routine weekly update on the ongoing buyback program. No new information on the pace or scope of the program. Monitor for any changes to the buyback authorization or completion announcement.
All NVO filing & press-release reports (43)
- 6-K reportNov 16, 2026
- COURT-RULING reportNov 13, 2026
- COURT-RULING reportNov 13, 2026
- 6-K reportNov 9, 2026
- INST-CLUSTER reportNov 5, 2026
- 6-K reportNov 5, 2026
- 6-K reportNov 4, 2026
- 6-K reportNov 3, 2026
- COURT-RULING reportOct 26, 2026
- 6-K reportOct 26, 2026
- 6-K reportOct 19, 2026
- 6-K reportOct 13, 2026
- 6-K reportOct 6, 2026
- 6-K reportSep 28, 2026
- COURT-RULING reportSep 23, 2026
- 6-K reportSep 21, 2026
- 6-K reportSep 17, 2026
- 6-K reportSep 15, 2026
- COURT-RULING reportSep 8, 2026
- 6-K reportSep 9, 2026
- COURT-RULING reportSep 3, 2026
- 6-K reportAug 24, 2026
- 6-K reportAug 18, 2026
- 6-K reportAug 10, 2026
- 6-K reportAug 10, 2026
- 6-K reportAug 4, 2026
- 6-K reportAug 4, 2026
- 6-K reportJul 31, 2026
- COURT-RULING reportJul 28, 2026
- COURT-RULING reportJul 24, 2026
- COURT-RULING reportJul 21, 2026
- 6-K reportJul 21, 2026
- 6-K reportJul 13, 2026
- COURT-RULING reportJul 10, 2026
- 6-K reportJul 6, 2026
- COURT-RULING reportJun 24, 2026
- 6-K reportJun 29, 2026
- COURT-RULING reportJun 10, 2026
- COURT-RULING reportFeb 3, 2026
- 6-K reportJun 24, 2026
- 6-K reportJun 15, 2026
- COURT-RULING reportMar 30, 2026
- 6-K reportMar 26, 2026